(Q37953115)

25 August 2017

title

Comprehensive handbook for developing a bladder cancer cystectomy database (English)

1 reference

25 August 2017

0 references

1 reference

1

Yair Lotan

1 reference

25 August 2017

13

Shahrokh F Shariat

1 reference

25 August 2017

Gilad Amiel

2

1 reference

25 August 2017

Stephen A Boorjian

3

1 reference

25 August 2017

Peter E Clark

4

1 reference

25 August 2017

Michael Droller

5

1 reference

25 August 2017

Jeffrey R Gingrich

6

1 reference

25 August 2017

Thomas J Guzzo

7

1 reference

25 August 2017

Brant A Inman

8

1 reference

25 August 2017

Ashish M Kamat

9

1 reference

25 August 2017

Larry Karsh

10

1 reference

25 August 2017

Matthew E Nielsen

11

1 reference

25 August 2017

Norm D Smith

12

1 reference

25 August 2017

Robert S Svatek

14

1 reference

25 August 2017

Jennifer M Taylor

15

1 reference

25 August 2017

Bladder Cancer Think Tank

16

1 reference

25 August 2017

Bladder Cancer Advocacy Network

17

1 reference

25 August 2017

publication date

6 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

31

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

812-826

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Precystectomy nomogram for prediction of advanced bladder cancer stage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Development of a comorbidity index using physician claims data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Imaging of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

State-of-the-art cross-sectional imaging in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Bladder cancer: can imaging change patient management?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Preoperative hydronephrosis as an indicator of survival after radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Prognostic significance of hydronephrosis in bladder cancer treated by radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological Stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Quality control in transurethral resection of bladder tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

When and how to treat superficial and muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

A second-look TUR in T1 transitional cell carcinoma: why?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Perioperative intravesical therapy after transurethral resection for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Is maintenance Bacillus Calmette-Guérin really necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Surgical benchmarks for the treatment of invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Hospital volume and surgical mortality in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Surgeon volume and operative mortality in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Surgical factors influence bladder cancer outcomes: a cooperative group report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The Will Rogers phenomenon in urological oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Bladder cancer: state-of-the-art care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Diagnosis and classification of flat, papillary, and invasive urothelial carcinoma: the WHO/ISUP consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Bladder cancer: a review of non-muscle invasive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Analysis of early complications after radical cystectomy: results of a collaborative care pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Early and late treatment-related morbidity following radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The changing pattern of mortality and morbidity from radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Incidence and risk factors of stomal complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Standards for surgical complication reporting in urologic oncology: time for a change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Quality of complication reporting in the surgical literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The MOS 36-ltem Short-Form Health Survey (SF-36)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Orthotopic neobladder versus ileal conduit urinary diversion after cystectomy--a quality-of-life based comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Quality-of-life assessment in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Determinants of quality of life of bladder cancer survivors five years after treatment in France.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion--a prospective cohort study with a systematic review of literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Clinical experience with the N-shaped ileal neobladder: assessment of complications, voiding patterns, and quality of life in our series of 58 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.09.004

10.1016/J.UROLONC.2011.09.004

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference